# ORIGINAL RESEARCH ARTICLE

#### Acta Scar

NOGS

# Screening for small-for-gestational-age fetuses

Ditte N. Hansen<sup>1,2</sup> | Helle S. Odgaard<sup>1</sup> | Niels Uldbjerg<sup>3,4</sup> | Marianne Sinding<sup>1,2</sup> | Anne Sørensen<sup>1,2</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, Aalborg University Hospital, Aalborg, Denmark

<sup>2</sup>Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

<sup>3</sup>Department of Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, Denmark

<sup>4</sup>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

#### Correspondence

Ditte N. Hansen, Department of Obstetrics and Gynecology, Aalborg University Hospital, Reberbansgade 15, 9000 Aalborg, Denmark.

Email: ditte\_n\_hansen@hotmail.com

#### **Funding information**

This study was supported by a grant from the Health Research Foundation of North Denmark Region.

#### Abstract

**Introduction:** It is well established that correct antenatal identification of small-forgestational-age (SGA) fetuses reduces their risk of adverse perinatal outcome with long-term consequences. Ultrasound estimates of fetal weight (EFW<sub>us</sub>) are the ultimate tool for this identification. It can be conducted as a "universal screening", that is, all pregnant women at a specific gestational age. However, in Denmark it is conducted as "selective screening", that is, only on clinical indication. The aim of this study was to assess the performance of the Danish national SGA screening program and the consequences of false-positive and false-negative SGA cases.

**Material and methods:** In this retrospective cohort study, we included 2928 women with singleton pregnancies with due dates in 2015. We defined "risk of SGA" by an  $EFW_{us} \leq -15\%$  of expected for the gestational age and "SGA" as birthweight  $\leq -22\%$  of expected for gestational age.

**Results:** At birth, the prevalence of SGA was 3.3%. The overall sensitivity of the Danish screening program was 62% at a false-positive rate of 5.6%. Within the entire cohort, 63% had an EFW<sub>us</sub> compared with 79% of the SGA cases. The sensitivity was 79% for those born before 37 weeks of gestation but only 40% for those born after 40 weeks of gestation. The sensitivity was also associated with birthweight deviation; 73% among extreme SGA cases (birthweight deviation ≤-33%) and 55% among mild SGA (birthweight deviation between -22% and -27%). False diagnosis of SGA was associated with an increased rate of induction of labor (OR<sub>adj</sub> = 2.51, 95% CI 1.70-3.71) and cesarean section (OR<sub>adj</sub> = 1.44, 95% CI 0.96-2.18).

**Conclusions:** The performance of the Danish national screening program for SGA based on selective EFW<sub>us</sub> on clinical indication has improved considerably over the last 20 years. Limitations of the program are the large proportion of women referred to ultrasound scan and the low performance post-term.

#### KEYWORDS

estimated fetal weight, outcome, performance, screening, small-for-gestational-age, ultrasound

Abbreviations: AGA, appropriate-for-gestational-age; BW, birthweight; EFW, estimated fetal weight; EFW<sub>us</sub>, ultrasound-based estimation of fetal weight; FPR, false-positive rate; GA, gestational age; OR, odds ratio; OR<sub>adj</sub>, adjusted odds ratio; SGA, small-for-gestational-age.

## 1 | INTRODUCTION

It is well established that small-for-gestational-age (SGA) fetuses are at increased risk of adverse perinatal outcome<sup>1</sup> and long-term consequences such as metabolic syndrome<sup>2</sup> and cardiovascular disease.<sup>3</sup> Antenatal detection of SGA improves the perinatal outcome by enabling timely delivery.<sup>4</sup> Unfortunately, false suspicion of SGA may increase the risk of unnecessary obstetric interventions and thereby increase the risk of adverse neonatal outcome.<sup>5</sup>

When using ultrasound in the screening for SGA, there are 2 approaches; "universal ultrasound screening" with routine ultrasound estimation of fetal weight (EFW<sub>us</sub>) conducted in all pregnant women at a specific gestational age (GA) and "selective ultrasound screening" with EFW<sub>us</sub> conducted only on clinical indication.

Universal EFW<sub>us</sub> screening has a sensitivity of 68%-77% (birthweight [BW] ≤3rd centile) at a false-positive rate (FPR) of 5%-13%<sup>6,7</sup> compared with selective EFW<sub>us</sub> screening with a sensitivity of 29%-32% at an FPR of 3%.<sup>7,8</sup> The performance of selective ultrasound screening is highly depended on the clinical indications used for referral of patients to EFW<sub>us</sub>, which dictates the proportion of women referred for ultrasound.

In Denmark, SGA is defined by a BW below -22% of the expected for GA<sup>9</sup> and the prevalence is approximately 3% among singleton pregnancies.<sup>8</sup> The routine antenatal fetal growth assessment includes clinical examination and symphysis-fundal height measurements performed by midwives and general practitioners every 3-4 weeks in pregnancy from 14 weeks of gestation until delivery. Only high-risk pregnancies based on the 1<sup>st</sup>-trimester risk stratification (previous obstetric or medical history) and complications in current pregnancy are referred to obstetric control including EFW<sub>us</sub>. If EFW<sub>us</sub> is  $\leq$ -15% of the expected weight for the GA, the fetus will be considered at risk of SGA.<sup>10</sup>

The most recent publication on selective  $\text{EFW}_{us}$  screening in Denmark was based on data from 1997-1998, where only 3.7% had an EFW, giving a sensitivity of 29% at an FPR of 0.26%.<sup>8</sup> However, based on clinical experience, the proportion of women referred for  $\text{EFW}_{us}$  has increased considerably over the last decades. Therefore, the actual performance of the screening for SGA in Denmark is currently unknown.

The aim of this study was to investigate the performance of the Danish national screening program for SGA including selective  $\text{EFW}_{us}$ . In addition, the obstetric consequences of false-positive and false-negative SGA cases are investigated.

## 2 | MATERIAL AND METHODS

We included all 3113 women with singleton pregnancies from Aalborg University Hospital, who according to their nuchal translucency scan had a due date between 1 January 2015 and 31 December 2015. The staff members were all certified by the Fetal Medicine Foundation.<sup>11</sup> A total of 185 women were excluded because of either abortion/miscarriage before 22 weeks of gestation or delivery

#### Key message

We assessed the performance of the Danish screening program for small-for-gestational-age fetuses for the first time in 20 years. Performance has improved considerably. In spite of a large proportion of women referred for additional ultrasound, the detection of small-for-gestationalage babies post-term remains low.

outside the North Denmark Region. Consequently, a total of 2928 women remained in the study.  $\text{EFW}_{us}$  (g) was calculated using the formula by Hadlock et al (based on head circumference, abdominal circumference and femur length)<sup>12</sup> and  $\text{EFW}_{us}$  deviation (%) was calculated using the reference curve by Maršál et al.<sup>9</sup>

Information regarding maternal characteristics, pregnancy and delivery were obtained from electronic patient records (CLINICAL SUITE<sup>™</sup> version 18.0.4.0; DXC Technology, Tysons, VA, USA) and the local Fetal Medicine database (ASTRAIA software gmbh version 1.24.10).

#### 2.1 | Statistical analyses

The performance of the national screening program for SGA was described by calculation of the sensitivity and the FPR using the binary cut-off value for expected SGA during pregnancy as  $EFW_{us} \leq -15\%$  and binary outcome for SGA at birth as  $BW \leq -22\%$ . Logistic regression was performed to compare the odds ratio (OR) of obstetric and neonatal outcomes between expected and unexpected groups of SGA and appropriate-for-gestational-age (AGA) neonates. ORs were adjusted for GA at birth, BW deviation, maternal body mass index and parity (OR<sub>adi</sub>).

The statistical software package STATA MP version 15.0 (StataCorp LP, College Station, TX, USA) was used for data analysis. *P* values <0.05 were considered statistically significant.

#### 2.2 | Ethical approval

The study was approved on 18 August 2016 and additional protocol was approved on 3 August 2018 by the Danish Patient Safety Authority, journal number 3-3013-1673/1. Data storage was approved by a regional notification to the Danish Data Protection Agency, journal number 2008-58-0028 with local reference-ID 2016-61 (31 March 2016) and 2018-104 (12 June 2018).

## 3 | RESULTS

Within this cohort of 2928 unselected singleton pregnancies, 3.3% had SGA when defined as BW  $\leq -22\%$  (Figure 1) and 63% had a selective EFW<sub>us</sub>. Concerning the entire cohort, the sensitivity

3



**FIGURE 1** Flowchart of the study population. AGA, appropriate-for-gestational-age; BW, birthweight;  $EFW_{us}$ , estimated fetal weight by ultrasound scan; SGA, small-for-gestational-age. SGA is defined by BW  $\leq -22\%$  (in accordance with Danish national guidelines) and for comparison by BW  $\leq -15\%$ 

was 62% given an FPR of 5.6% for SGA defined as BW  $\leq$  -22%. Performance for SGA defined as BW  $\leq$  -15% is added for comparison (Table 1). For those with mild SGA (BW -22% to -27%), the sensitivity of the screening program was 55%; for those with extreme SGA (BW  $\leq$  33%) it was 73% (see Supplementary material, Table S1); whereas it was only 40% (14/35) for newborns delivered after 40<sup>+0</sup> weeks (Table 2).

For the calculation of these sensitivities, we defined "screen positive" by the last  $\text{EFW}_{us} \leq -15\%$ .<sup>10</sup> Using an  $\text{EFW}_{us} \leq -12\%$  would give a sensitivity of 86% at an FPR of 17%; using  $\text{EFW}_{us} \leq -22\%$ , would give a sensitivity 57% at a FPR of 1.6% (see Supplementary material, Table S2).

The maternal and neonatal characteristics for the SGA and AGA pregnancies are presented in the Supplementary material, Table S3 (SGA) and Table S4 (AGA).

Among the SGA fetuses, we could not demonstrate different perinatal outcomes among those identified by  $\text{EFW}_{us}$  and those not identified by  $\text{EFW}_{us}$  (Table 3) even though the identified SGA were more likely to have induction of labor ( $OR_{adj} = 0.13, 95\%$  CI 0.04-0.41) and elective cesarean section (27% vs 0%, *P* < 0.01). Among the AGA fetuses, 5.6% were falsely expected to be SGA and these were more likely to have induction of labor ( $OR_{adj} = 2.51, 95\%$  CI 1.70-3.71) and cesarean delivery ( $OR_{adj} = 1.44, 95\%$  CI 0.96-2.18) (Table 4).

 
 TABLE 1
 Performance of the screening program for small-forgestational-age in Denmark

Total population, n	2928	
Women never referred to ultrasound	37% (1079/2928)	
Women referred to ultrasound	63% (1849/2928)	
Time between last ultra- sound and birth (days), median (interquartile range)	11 (2, 28)	
SGA cut-off	BW ≤ −22%	BW ≤ −15%
SGA at birth	3.3% (98/2928)	10.3% (303/2928)
Last EFW <sub>us</sub> ≤ −15%	7.5% (219/2928)	7.5% (219/2928)
Sensitivity (last EFW <sub>us</sub> ≤ −15% and SGA at birth)	62% (61/98)	41.6% (126/303)
False-positive rate	5.6% (158/2830)	3.5% (93/2625)

*Note:* SGA is defined by BW  $\leq$  -22% (in accordance with Danish national guidelines) and for comparison by BW  $\leq$  -15%.

Abbreviations: BW, birthweight;  $\text{EFW}_{us}$ , estimated fetal weight by ultrasound scan; SGA, small-for-gestational-age.



TABLE 2 Performance of the screening program for small-for-gestational-age in Denmark in relation to gestational age at birth

		Gestational age at birth				
	Overall	<34 weeks	34 <sup>0</sup> -36 <sup>6</sup> weeks	37 <sup>0</sup> -39 <sup>6</sup> weeks	40 <sup>0</sup> -40 <sup>6</sup> weeks	≥41 weeks
Total population, n	2928	46	130	1,146	845	761
SGA at birth (BW ≤ −22%)	3.3% (98/2928)	24% (11/46)	10% (13/130)	3.4% (39/1146)	2.2% (19/845)	2.1% (16/761)
Sensitivity of screen- ing program	62% (61/98)	73% (8/11)	85% (11/13)	72% (28/39)	42% (8/19)	38% (6/16)
SGA referred to ultrasound	79% (77/98)	82% (9/11)	92% (12/13)	90% (35/39)	68% (13/19)	50% (8/16)
Last EFW <sub>us</sub> ≤ −15%	7.5% (219/2928)	26% (12/46)	15% (20/130)	8.6% (99/1146)	4.7% (40/845)	6.3% (48/761)
False-positive rate	5.6% (158/2830)	11% (4/35)	7.7% (9/117)	6.4% (71/1107)	3.9% (32/826)	5.6% (42/745)

Note: Sensitivity for SGA defined by BW  $\leq -22\%$  using the following cut-off; EFW<sub>us</sub>  $\leq -15\%$  at last ultrasound scan.

Abbreviations: BW, birthweight; EFW<sub>us</sub>, estimated fetal weight by ultrasound scan; SGA, small-for-gestational-age.

TABLE 3 Outcome for small-for-gestational-age pregnancies

	SGA				
Outcome	Total n = 98	Expected SGA (Last EFW <sub>us</sub> ≤ −15%) n = 61	Expected AGA (Last EFW <sub>us</sub> > -15% or no EFW <sub>us</sub> ) n = 37	OR (95% CI), P-value	Adjusted <sup>a</sup> OR (95% CI), <i>P</i> -value
Cesarean delivery	36% (35/98)	47% (26/61)	24% (9/37)	0.43 (0.17-1.07), <i>P</i> = 0.07	0.71 (0.24-2.13), P = 0.54
Elective cesarean section among all cesarean sections	20% (7/35)	27% (7/26)	0	**	**
Intended vaginal delivery	77% (75/98)	72% (44/61)	84% (31/37)	2.31 (0.93-5.72), P = 0.07	1.41 (0.47-4.22), P = 0.54
Induction among intended vaginal deliveries	57% (44/75)	83% (34/44)	35% (10/31)	0.14 (0.05-0.39), P = 0.00*	0.13 (0.04-0.41), <i>P</i> = 0.00*
Vacuum among vaginal deliveries	13% (8/63)	17% (6/35)	7.1% (2/28)	0.37 (0.07-2.01), P = 0.25	0.41 (0.07-2.30), <i>P</i> = 0.31
Umbilical artery pH <7.1	7.0% (6/86)	7.1% (4/56)	6.7% (2/30)	0.93 (0.16-5.39), P = 0.93	0.54 (0.08-3.58), P = 0.52
Apgar score <7 after 5 min	4.2% (4/95)	5.0% (3/60)	2.9% (1/35)	0.56 (0.06-5.59), P = 0.62	0.50 (0.04-5.78), <i>P</i> = 0.58
Stillborn	2.0% (2/98)	1.6% (1/61)	2.7% (1/37)	1.67 (0.10-27.47), P = 0.72	0.66 (0.02-27.39), P = 0.83
Neonatal death	1.0% (1/98)	1.6% (1/61)	0	**	**
Adverse outcome <sup>b</sup>	11% (11/98)	13% (8/61)	8.1% (3/37)	0.58 (0.14-2.36), P = 0.45	0.53 (0.12-2.37), P = 0.41

Note: SGA = BW  $\leq -22\%$ . Expected SGA = EFW<sub>us</sub>  $\leq -15\%$  at last ultrasound scan. Expected AGA = normal symphysis-fundal height measurements and/or EFW<sub>us</sub>  $\geq -15\%$  at last ultrasound scan. Logistic regressions are used to compare the groups of SGA (expected SGA and expected AGA) using SGA-expected SGA as a reference.

Abbreviations: AGA, appropriate-for-gestational-age; CI, confidence interval; EFW<sub>us</sub>, estimated fetal weight by ultrasound scan; OR, odds ratio; SGA, small-for-gestational-age.

<sup>a</sup>Adjusted for gestational age at birth (weeks in total), birthweight deviation (%), maternal body mass index and parity.

<sup>b</sup>Umbilical artery pH <7.1, Apgar score <7 after 5 min, stillborn and neonatal death in 1 variable.

\*P<0.05.

\*\*Logistic regression not possible, because no cases within expected AGA group.

## 4 | DISCUSSION

In this study, we investigated the performance of the screening program for SGA defined as BW  $\leq -22\%$  in the North Denmark Region based on selective EFW<sub>us</sub>. No less than 63% had an EFW<sub>us</sub> giving a sensitivity of 62%; however this was much higher for fetuses with extreme SGA. We could not demonstrate improved perinatal outcome among SGA fetuses identified by  $\text{EFW}_{us}$  when compared with those not identified by  $\text{EFW}_{us}$ . The FPR was 5.6% and false-positive SGA cases were at an increased risk of obstetric interventions.

It is a strength of this study that the cohort can be classified as unselected, because we included >95% of the pregnant population

TABLE 4 Outcome for appropriate-for-gestational-age pregnancies

	AGA				
Outcome	Total n = 2830	Expected AGA (Last EFW <sub>us</sub> > -15% or no EFW <sub>us</sub> ) n = 2672	Expected SGA (Last EFW <sub>us</sub> ≤ −15%) n = 158	OR (95% CI), P-value	Adjusted <sup>a</sup> OR (95% CI), P-value
Cesarean delivery	20% (572/2830)	20% (535/2672)	23% (37/158)	1.22 (0.84-1.79), P = 0.30	1.44 (0.96-2.18), P = 0.08
Elective cesarean sec- tion among all cesarean sections	38% (215/572)	38% (203/535)	32% (12/37)	0.79 (0.39-1.60), P = 0.50	1.49 (0.68-3.26), P = 0.32
Intended vaginal delivery	83% (2349/2830)	83% (2221/2672)	81% (128/158)	0.82 (0.56-1.20), P = 0.30	0.69 (0.46-1.05), P = 0.08
Induction among intended vaginal deliveries	29% (688/2349)	28% (631/2221)	45% (57/128)	2.02 (1.41-2.90), <i>P</i> = 0.00*	2.51 (1.70-3.71), <i>P</i> = 0.00*
Vacuum among vaginal deliveries	8.3% (187/2258)	8.4% (179/2137)	6.6% (8/121)	0.77 (0.37-1.61), <i>P</i> = 0.49	0.66 (0.31-1.44), <i>P</i> = 0.30
Umbilical artery pH <7.1	4.6% (118/2590)	4.6% (113/2443)	3.4% (5/147)	0.73 (0.29-1.81), P = 0.49	0.73 (0.28-1.87), P = 0.51
Apgar score <7 after 5 min	0.8% (22/2812)	0.8% (21/2654)	0.6% (1/158)	0.80 (0.11-5.98), <i>P</i> = 0.83	0.65 (0.08-5.22), P = 0.68
Stillborn	0.3% (9/2830)	0.3% (9/2672)	0	**	**
Neonatal death	0.1% (2/2830)	0.8% (2/2672)	0	**	**
Adverse outcome <sup>b</sup>	5.1% (144/2830)	5.2% (138/2672)	3.8% (6/158)	0.72 (0.31-1.67), P = 0.45	0.63 (0.27-1.50), P = 0.30

Note: AGA = BW > -22%. Expected SGA =  $EFW_{us} \le -15\%$  at last ultrasound scan. Expected AGA = normal symphysis-fundal height measurements and/or  $EFW_{us} > -15\%$  at last ultrasound scan. Logistic regressions are used to compare the groups of AGA (expected AGA and expected SGA) using AGA-expected AGA as a reference

Abbreviations: AGA, appropriate-for-gestational-age; CI, confidence interval; EFW<sub>us</sub>, estimated fetal weight by ultrasound scan; OR, odds ratio; SGA, small-for-gestational-age.

<sup>a</sup>Adjusted for gestational age at birth (weeks in total), birthweight deviation (%), maternal body mass index and parity.

<sup>b</sup>Umbilical artery pH <7.1, Apgar score <7 after 5 min, stillborn and neonatal death in one variable.

\*P<0.05.

\*\*Logistic regression not possible, because no cases within expected SGA group.

in a well-defined geographic area<sup>13</sup> with a lost to follow-up rate of only 5.9%. Furthermore, the validity of the data was very high because it is based on the unique Danish personal identification number. It is a limitation that the study is not powered to assess rare neonatal outcomes. In addition, referral for EFW<sub>us</sub> followed the national guidelines. Unfortunately, the specific indication for referral is not consistently available in the patient record, and therefore the association between SGA and specific indications cannot be evaluated in this study.

In this study, the sensitivity of SGA screening using selective  $EFW_{us}$  on clinical indication was 62%, which is markedly higher than previous studies on selective ultrasound screening reporting a sensitivity of 29%-46%.<sup>7,8,14</sup> This could be explained by a larger proportion of women referred to  $EFW_{us}$  in our study (63%) compared with previous studies (3.7%-42%).<sup>7,8,14</sup> The large proportion of women referred to  $EFW_{us}$  may partly be explained by the inclusion of multiparous women in our study (54% of the total cohort). Among multiparous women, indications for  $EFW_{us}$  include previous obstetric complications such as SGA or preeclampsia, which lead to a higher number of referrals.<sup>10,15</sup> Moreover, the referral pattern in Aalborg and Denmark might be different from that in other countries.<sup>10</sup> Even with such a large proportion of all women referred for ultrasound,

21% of SGA pregnancies were not referred for  $EFW_{us}$ . Moreover, a large proportion of AGA pregnancies (63%) underwent  $EFW_{us}$ .

We defined a screen-positive case in accordance with the national guidelines on SGA screening as last  $EFW_{iis} \leq -15\%$ , that is, by a relatively slight estimated weight deviation. Therefore, it is disappointing that the sensitivity was only 73% (8/11) for extreme SGA (BW  $\leq$  -33%); 2 cases did not have an EFW<sub>us</sub> due to a false-negative "clinical screening" based on risk factors and symphysis-fundal height measurement; 1 case had an EFW<sub>us</sub> > -15%, which was performed 29 days before birth (see Supplementary material, Table S1). Previous publications have not addressed this extreme SGA sensitivity even though these cases are most in need of prenatal detection and must be the primary target when we consider potential improvements to our screening program, as discussed below. It is more acceptable that the sensitivity for mild SGA (BW between -22% and -27%) was only 55% (29/53) even though they might also benefit from prenatal detection, especially when born post term.<sup>16</sup> In fact, the  $\mathsf{EFW}_{us}$  standard deviation of 8% when using The Hadlock Formula<sup>12</sup> implies that a significant fraction of mild SGA fetuses will remain undetected (EFW<sub>us</sub> > -15%) even when identified by the clinical screening (eg symphysis-fundal height) with correct referral for EFW<sub>us</sub>.

The sensitivity decreased markedly with increasing GA; from 72% (GA  $37^{+0}$ - $39^{+6}$ ) to 38% (GA  $\ge 41^{+0}$ ) leaving 22% (21/98) undiagnosed at birth after term (Table 2). Among these, 67% (14/21) did not have an EFW<sub>us</sub>, whereas 33% (7/21) had an EFW<sub>us</sub> > -15%. This is highly problematical, because it is generally accepted that SGA babies need to be delivered at least at term.<sup>16</sup>

We confirmed the results from a Swedish<sup>4</sup> study showing increased risk of interventions among SGA cases identified correctly before birth (Table 3). However, our study did not have statistical power to address their finding of improved neonatal outcome. The FPR is also of interest, that is, AGA cases falsely expected to be SGA (Table 4), showed an increased rate of labor induction ( $OR_{adj}$  2.51, 95% CI 1.70-3.71) and an increased cesarean section rate ( $OR_{adj}$  1.44, 95% CI 0.96-2.18) confirming results from 1 previous study.<sup>5</sup>

In order to improve the screening for SGA in Denmark, several issues could be considered: selection of pregnancies for EFW,..., accuracy of  $\mathsf{EFW}_{us}$ , and 3rd trimester routine  $\mathsf{EFW}_{us}$  ("universal ultrasound screening"). Improved selection of pregnancies for EFW<sub>ue</sub> might be achieved by the use of 1st trimester maternal serum markers<sup>17,18</sup> and uterine artery Doppler flow,<sup>19,20</sup> and by improved symphysis-fundal height measurements using a single person throughout the pregnancy.<sup>21,22</sup> An obvious possibility would be to change the "risk of SGA" definition to  $\mathsf{EFW}_{\mathsf{us}} \leq -12\%$  on the expense of a doubled FPR. Furthermore 3-dimensional ultrasound<sup>23</sup> and magnetic resonance imaging<sup>24,25</sup> for better estimates of EFW could be considered. Introduction of routine EFW<sub>us</sub> ("universal ultrasound screening") has been shown to increase the sensitivity from 29%-33% to 42%-80%, but at the expense of increased FPR from 0.26%-3% to 5%-13% in previous studies.<sup>7,14,26,27</sup> Routine EFW<sub>us</sub> performs best when applied close to delivery<sup>26,27</sup>; that is, a sensitivity of 89% if delivery is within 2 weeks from routine  $\mathsf{EFW}_{\mathsf{us}}$  in GA 35-37 weeks, at an FPR of 5%.<sup>27</sup> As suggested by our data, the main limitation of the Danish SGA screening program was in the antenatal detection of post-term SGA infants. Therefore, introducing a late routine EFW<sub>us</sub> either at term or post-term (GA 41<sup>+0</sup>) would likely increase the sensitivity but also the FPR.

This manuscript focuses on screening for SGA, as small fetal size is regarded as a proxy of placental dysfunction. However, fetal size is not a perfect marker of placental function, and even a perfect screening for SGA may not identify all fetuses at risk because of placental dysfunction.<sup>28</sup> New markers of placental dysfunction based on maternal serum<sup>18</sup> or placental MRI<sup>29</sup> may be able to identify placental dysfunction directly, and the clinical potential of these methods is currently being investigated.

## 5 | CONCLUSION

The performance of the Danish national screening program for SGA based on selective  $\text{EFW}_{us}$  on clinical indication has improved considerably over the last 20 years with an increased sensitivity from 29% (1998) to 62% (2015) and FPR from 0.26% (1998) to 5.6% (2015).<sup>8</sup> However, the selection of pregnancies for ultrasound is a limitation

of the program as a large proportion of AGA pregnancies are referred to ultrasound and a large proportion of SGA pregnancies are not. In addition, the detection of SGA babies post-term remains rather low when compared with earlier gestation. This paper gives a detailed insight into the current screening program, and provides ideas for further improvement of SGA screening.

#### ACKNOWLEDGMENTS

We wish to thank Hans-Victor Nielsen, academic secretary, for fruitful help with data collection.

#### CONFLICT OF INTEREST

The authors declare no conflicts of interest.

#### REFERENCES

- Pallotto EK, Kilbride HW. Perinatal outcome and later implications of intrauterine growth restriction. *Clin Obstet Gynecol*. 2006;49(2):257-269.
- Hofman PL, Cutfield WS, Robinson EM, et al. Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrinol Metab. 1997;82(2):402-406.
- Eriksson JG, Forsén T, Tuomilehto J, Osmond C, Barker DJP. Early growth and coronary heart disease in later life: longitudinal study. BMJ. 2001;322:949-953.
- 4. Lindqvist PG, Molin J. Does antenatal identification of small-for-gestational age fetuses significantly improve their outcome? *Ultrasound Obstet Gynecol.* 2005;25(3):258-264.
- Gabbay-Benziv R, Aviram A, Hadar E, et al. Pregnancy outcome after false diagnosis of fetal growth restriction. J Matern Fetal Neonatal Med. 2017;30(16):1916-1919.
- Triunfo S, Crovetto F, Scazzocchio E, et al. Contingent versus routine third-trimester screening for late fetal growth restriction. *Ultrasound Obstet Gynecol.* 2016;47(1):81-88.
- Sovio U, White IR, Dacey A, Pasupathy D, Smith GCS. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. *Lancet*. 2015;386(10008):2089-2097.
- Westergaard HB, Langhoff-Roos J. Doppler ultrasonography in singleton pregnancies at risk of intrauterine growth retardation—a national estimate. Acta Obstet Gynecol Scand. 2002;81(6):534-539.
- Marsál K, Persson P-H, Larsen T, et al. Intrauterine growth curves based on ultrasonically estimated foetal weights. *Acta Paediatr*. 1996;85(7):843-848.
- Gjerris AC, Pinborg A, Shalmi A-C, et al. IUGR-guideline (in Danish) [Internet]. Danish Society of Obstetrics and Gynecology; 2014. p. 1-80. Available from: http://static.squarespace.com/static/5467a bcce4b056d72594db79/546e7748e4b0d969a4f6cf10/546e7 746e4b0d969a4f6cc60/1395263284000/FGR.pdf?forma t=original
- 11. Robinson HP, Fleming JE. A critical evaluation of sonar "crown-rump length" measurements. Br J Obstet Gynaecol. 1975;82(9):702-710.
- 12. Hadlock FP, Harrist RB, Carpenter RJ, Deter RL, Park SK. Sonographic estimation of fetal weight. *Radiology*. 1984;150:535-540.
- Ekelund CK, Kopp TI, Tabor A, Petersen OB. The Danish fetal medicine database. *Clin Epidemiol*. 2016;8:479-483.
- 14. Skråstad RB, Eik-Nes SH, Sviggum O, et al. A randomized controlled trial of third-trimester routine ultrasound in a non-selected population. *Acta Obstet Gynecol Scand*. 2013;92(12):1353-1360.
- Ananth CV, Peltier MR, Chavez MR, et al. Recurrence of ischemic placental disease. *Obstet Gynecol.* 2007;110(1):128-133.

- Pilliod RA, Cheng YW, Snowden JM, Doss AE, Caughey AB. The risk of intrauterine fetal death in the small-for-gestational-age fetus. *Am J Obstet Gynecol*. 2012;207(4):318.e1-318.e6.
- Bakalis S, Peeva G, Gonzalez R, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30–34 weeks. *Ultrasound Obstet Gynecol*. 2015;46(4):446-451.
- Bakalis S, Gallo DM, Mendez O, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30–34 weeks. Ultrasound Obstet Gynecol. 2015;46(2):208-215.
- Fadigas C, Guerra L, Garcia-Tizon Larroca S, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 35–37 weeks. Ultrasound Obstet Gynecol. 2015;45(6):715-721.
- Bakalis S, Stoilov B, Akolekar R, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 30–34 weeks. Ultrasound Obstet Gynecol. 2015;45(6):707-714.
- Pattinson RC, Theron GB. Inter-observer variation in symphysis-fundus measurements. a plea for individualised antenatal care. S Afr Med J. 1989;76(11):621-622.
- Morse K, Williams A, Gardosi J. Fetal growth screening by fundal height measurement. Best Pract Res Clin Obstet Gynaecol. 2009;23(6):809-818.
- Lee W, Deter R, Sangi-Haghpeykar H, Yeo L, Romero R. Prospective validation of fetal weight estimation using fractional limb volume. Ultrasound Obstet Gynecol. 2013;41(2):198-203.
- Kadji C, Camus MF, Bevilacqua E, et al. Repeatability of estimated fetal weight: comparison between MR imaging versus 2D ultrasound in at- and near-term patients. *Eur J Radiol.* 2017;91:35-40.

- 25. Matthew J, Malamateniou C, Knight CL, et al. A comparison of ultrasound with magnetic resonance imaging in the assessment of fetal biometry and weight in the second trimester of pregnancy: an observer agreement and variability study. Ultrasound. 2018;26(4):229-244.
- Bakalis S, Silva M, Akolekar R, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by fetal biometry at 30–34 weeks. Ultrasound Obstet Gynecol. 2015;45(4):551-558.
- Fadigas C, Saiid Y, Gonzalez R, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by fetal biometry at 35–37 weeks. Ultrasound Obstet Gynecol. 2015;45:559-565.
- Thilaganathan B. Ultrasound fetal weight estimation at term may do more harm than good. *Ultrasound Obstet Gynecol.* 2018;52(1): 5-8.
- Sinding M, Peters DA, Frøkjaer JB, et al. Placental T2\* measurements in normal pregnancies and in pregnancies complicated by fetal growth restriction. Ultrasound Obstet Gynecol. 2016;47:748-754.

#### SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Hansen DN, Odgaard HS, Uldbjerg N, Sinding M, Sørensen A. Screening for small-forgestational-age fetuses. *Acta Obstet Gynecol Scand*. 2019;00:1–7. https://doi.org/10.1111/aogs.13764

		Birthweight-deviation (%)		
	Overall	≤ -22% to > -27%	$\leq$ -27% to > -33%	≤-33 %
SGA at birth (BW≤-22%), n	98	53	34	11
Sensitivity of total screening program, n=98	62% (61/98)	55% (29/53)	71% (24/34)	73% (8/11)
SGA referred to ultrasound scan	79% (77/98)	77% (41/53)	79% (27/34)	82% (9/11)
Sensitivity among patients referred to ultrasound, n=77	79% (61/77)	71% (29/41)	89% (24/27)	89% (8/9)

**TABLE S1:** Performance of the screening program for SGA in Denmark in relation to birthweight deviation.

Sensitivity for SGA defined by  $BW \leq -22\%$  using the following cut off;  $EFW_{us} \leq -15\%$  at last ultrasound scan. SGA, small-for-gestational-age.  $EFW_{us}$ , estimated fetal weight by ultrasound scan. BW, birthweight.

Population n=1849 SGA ( $PW \leq 22\%$ ) n=77	Estimated fetal weight cut-off value					
30A (BW≦-22%) II=77	EFW <sub>us</sub> -12%	EFW <sub>us</sub> -15%	EFW <sub>us</sub> -18%	EFW <sub>us</sub> -22%		
Last $EFW_{us} \leq -15\%$ , n	367	219	133	73		
True positive, n	66	61	54	44		
Sensitivity	86% (66/77)	79% (61/77)	70% (54/77)	57% (44/77)		
False positive rate	17% (301/1772)	8.9% (158/1772)	4.5% (79/1772)	1.6% (29/1772)		

TABLE S2: Screening performance at different ultrasound estimated fetal weight (EFW<sub>us</sub>) cut-off values

Included in this table are only patients referred to ultrasound scan (n=1849).

SGA, small-for-gestational-age.  $EFW_{us}$ , estimated fetal weight by ultrasound scan. BW, birthweight.

Table S3: Maternal and neonatal characteristics of SGA-pregnancies.

	SGA				
Characteristics	Total	<b>Expected SGA</b> (last EFW <sub>us</sub> ≤-15%)	Expected AGA (last EFW <sub>us</sub> >-15% or no EFW <sub>us</sub> )	<i>P</i> -value	
	n=98	n=61	n=37		
Gestational age at birth (weeks)	39.1 (37.0, 40.6)	38.3 (36.4, 39.7)	40.4 (38.6, 41.0)	0.0007*	
Birthweight (gram)	2458 (2115, 2688)	2380 (2008, 2605)	2650 (2360, 2815)	0.0008*	
Birthweight deviation (%)	-26.5 (-29.6, -23.3)	-27.5 (-30.4, -24.1)	-24.9 (-28.1, -22.7)	0.008*	
Number of ultrasound examinations (with EFW <sub>us</sub> )	2 (1, 4)	3 (2, 5)	0 (0, 2)	0.00*	
Gestational age at last ultrasound (weeks)	37.0 (35.1, 38.9)	37.1 (35.6, 39.1)	36.5 (34.8, 37.5)	0.13	
Time between last ultrasound and birth (days)	4 (1, 11)	2 (1, 6.5)	22 (6.8, 31)	0.00*	
Girls	57 (58%)	35 (57%)	22 (60%)	0.84	
Maternal Body Mass Index (kg/m <sup>2</sup> )	23.7 (21.6, 27.6)	23.7 (21.0, 28.1)	23.6 (22.0, 26.5)	0.84	
Maternal age (years)	29 (25, 34)	28 (24.5, 33)	30 (26.5, 34)	0.21	
Nulliparous	62 (63%)	37 (61%)	25 (68%)	0.49	
Cigarette smoker	22 (22%)	16 (26%)	6 (16%)	0.25	
Maternal hypertensive disorders	18 (18%)	16 (26%)	2 (5.4%)	0.01*	
Maternal diabetic disorders	2 (2.0%)	1 (1.6%)	1 (2.7%)	0.72	

 $SGA = BW \leq -22\%$ . Expected  $SGA = EFW_{us} \leq -15\%$  at last ultrasound scan. Expected AGA = normal symphysis-fundal-height measurements and/or  $EFW_{us} > -15\%$  at last ultrasound scan. Data are presented as median (interquartile range) or n (%). Comparison of characteristics between groups of SGA (expected SGA and expected AGA) by Chi<sup>2</sup> test for categorical variable and by Mann-Whitney U test for continuous variables. \* P<0.05. SGA, small-for-gestational-age. AGA, appropriate-for-gestational-age. EFW<sub>us</sub>, estimated fetal weight by ultrasound scan.

## **TABLE S4:** Maternal and neonatal characteristics of AGA-pregnancies.

		AGA		
Characteristics	Total	Expected AGA (Last EFW <sub>us</sub> >-15% or no EFW <sub>us</sub> )	Expected SGA (Last EFW <sub>us</sub> <-15%)	<i>P</i> -value
	n=2830	n= 2672	n=158	
Gestational age at birth (weeks)	40.1 (39.0, 41.0)	40.1 (39.0, 41.0)	39.9 (38.6, 41.0)	0.06
Birthweight (gram)	3585 (3250, 3900)	3620 (3291, 3929)	3045 (2750, 3273)	0.00*
Birthweight deviation (%)	-0.1 (-7.4, 8.5)	0.5 (-6.1, 9.0)	-14 (-17, -9.8)	0.00*
Number of ultrasound examinations (with EFW <sub>us</sub> )	1 (0, 2)	1 (0, 2)	3 (1, 4)	0.00*
Gestational age at last ultrasound (weeks)	37.1 (35.3, 39.7)	37.0 (35.3, 39.6)	38.1 (36.6, 40.1)	0.0001*
Time between last ultrasound and birth (days)	12 (3, 29)	13 (3, 30)	4 (1, 14)	0.00*
Girls	1,346 (48%)	1,261 (47%)	85 (54%)	0.11
Maternal Body Mass Index (kg/m <sup>2</sup> )	23.9 (21.5, 27.7)	24.0 (21.6, 27.7)	22.7 (20.5, 26.0)	0.0003*
Maternal age (years)	29.5 (26, 33)	30 (26, 33)	29 (26, 33)	0.65
Nulliparous	1,299 (46%)	1,216 (46%)	83 (53%)	0.09
Cigarette smoker	233 (8.2%)	212 (7.9%)	21 (13%)	0.08
Maternal hypertensive disorders	120 (4.2%)	106 (4.0%)	14 (8.9%)	0.003*
Maternal diabetic disorders	168 (5.9%)	162 (6.1%)	6 (3.8%)	0.24

AGA = BW > -22%. Expected  $SGA = EFW_{us} \le -15\%$  at last ultrasound scan. Expected AGA = normal symphysis-fundal-height measurements and/or  $EFW_{us} > -15\%$  at last ultrasound scan. Data are presented as median (interquartile range) or n (%). Comparison of characteristics between groups of AGA (expected AGA and expected SGA) by Chi<sup>2</sup> test for categorical variable and by Mann-Whitney U test for continuous variables. \* P<0.05. SGA, small-for-gestational-age. AGA, appropriate-for-gestational-age. EFW<sub>us</sub>, estimated fetal weight by ultrasound scan.